Biomarkers of cognitive decline in Parkinson's disease

Parkinsonism & Related Disorders
Chin-Hsien Lin, Ruey-Meei Wu

Abstract

Cognitive impairment is a frequent and devastating non-motor symptom of Parkinson's disease (PD). Impaired cognition has a major impact on either quality of life or mortality in patients with PD. Notably, the rate of cognitive decline and pattern of early cognitive deficits in PD are highly variable between individuals. Given that the underlying mechanisms of cognitive decline or dementia associated with PD remain unclear, there is currently no mechanism-based treatment available. Identification of biological markers, including neuroimaging, biofluids and common genetic variants, that account for the heterogeneity of PD related cognitive decline could provide important insights into the pathological processes that underlie cognitive impairment in PD. These combined biomarker approaches will enable early diagnosis and provide indicators of cognitive progression in PD patients. This review summarizes recent advances in the development of biomarkers for cognitive impairments in PD.

References

Jan 1, 1992·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·J A DetreA P Koretsky
Jun 1, 1988·Journal of Neurology, Neurosurgery, and Psychiatry·W R Gibb, A J Lees
Jun 1, 1988·Neurology·E GroberR Dresner
Mar 1, 1983·Annals of Neurology·P J WhitehouseD L Price
Sep 1, 1994·Journal of Neuropathology and Experimental Neurology·S H HanD E Schmechel
Jul 1, 1996·Brain and Cognition·D P SalmonR Katzman
Feb 16, 1996·Neuroscience Letters·S HelisalmiH Soininen
Aug 17, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·A SchragN Quinn
Mar 29, 2001·Neurology·D AarslandP Kragh-Sørensen
Feb 15, 2002·Brain : a Journal of Neurology·A J HardingG M Halliday
Apr 26, 2003·Science·Benoit I GiassonVirginia M-Y Lee
Oct 7, 2003·Neuromolecular Medicine·Benoit I GiassonJohn Q Trojanowski
Dec 15, 2004·Archives of Neurology·Dag AarslandPer Kragh-Sørensen
Oct 21, 2005·Neurology·I G McKeithUNKNOWN Consortium on DLB
Jan 18, 2006·Acta Neurologica Scandinavica·G A MarshallN I Bohnen
Sep 27, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Emma J BurtonJohn T O'Brien
Nov 15, 2006·Neurology·James E GalvinJohn C Morris
Feb 14, 2007·Archives of Neurology·Barbara Jasinska-MygaJadwiga Tyrpa
Mar 14, 2007·Neurology·C F LippaUNKNOWN DLB/PDD Working Group
May 18, 2007·Journal of Neurology·D AarslandK Marder
May 31, 2007·Brain : a Journal of Neurology·C H Williams-GrayR A Barker
Feb 15, 2008·Acta Neuropathologica·Kurt A Jellinger, Johannes Attems
Apr 9, 2008·Parkinsonism & Related Disorders·M K Beyer, D Aarsland
Sep 17, 2008·Neurology·S N GompertsK A Johnson
Nov 21, 2008·Neurology·D AarslandUNKNOWN Norwegian ParkWest Study Group
Jan 24, 2009·Neurobiology of Disease·Walter MaetzlerDaniela Berg
Mar 17, 2009·Brain : a Journal of Neurology·Juliane NeumannNicholas W Wood
Mar 27, 2009·Journal of Geriatric Psychiatry and Neurology·Martin Wilhelm KurzGuido Alves
Oct 9, 2009·Brain : a Journal of Neurology·Caroline H Williams-GrayRoger A Barker
Oct 31, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Naroa Ibarretxe-BilbaoMaria-Jose Marti
Apr 8, 2010·Brain : a Journal of Neurology·Peter A KempsterAndrew J Lees

❮ Previous
Next ❯

Citations

Aug 21, 2015·Expert Review of Neurotherapeutics·Umer Akbar, Joseph H Friedman
Jan 18, 2016·Parkinsonism & Related Disorders·Oury MonchiPierre Bellec
Jan 21, 2016·Parkinson's Disease·Johannes LangeJodi Maple-Grødem
Sep 28, 2015·Neuroscience and Biobehavioral Reviews·Carol P WeingartenNan-kuei Chen
Sep 1, 2015·Parkinsonism & Related Disorders·Gabriella SantangeloPaolo Barone
Jul 15, 2015·Behavioural Brain Research·Emre BoraDennis Velakoulis
May 6, 2016·Parkinson's Disease·Vitalii V CozacPeter Fuhr
May 30, 2015·Chemical Communications : Chem Comm·Wen Xiu RenJong Seung Kim
Apr 21, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Carme UribeCarme Junque
Jun 15, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Kyle B FraserAndrew B West
Aug 24, 2016·Human Movement Science·Gustavo ChristofolettiGammon M Earhart
Mar 4, 2017·Nature Reviews. Neurology·Dag AarslandClive Ballard
Mar 8, 2018·BMC Medicine·Kurt A Jellinger, Amos D Korczyn
Mar 15, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Yu GuoJin-Tai Yu
May 28, 2017·Journal of Neurology, Neurosurgery, and Psychiatry·Chin-Hsien LinMing-Jang Chiu
Feb 27, 2018·Journal of Parkinson's Disease·Annekatrin KönigTiago Fleming Outeiro
Jan 24, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Miyeong GangKyoko Suzuki
Oct 1, 2016·Dementia & Neuropsychologia·Maira Rozenfeld OlchikCarlos Roberto Mello Rieder
Jul 5, 2017·Frontiers in Aging Neuroscience·Deborah L HarringtonChelsea French
Jul 22, 2018·CNS Drugs·Christoph MuellerDag Aarsland
Aug 21, 2019·Translational Neurodegeneration·Shirley Yin-Yu PangShu-Leong Ho
Jan 31, 2017·Journal of the Neurological Sciences·Myrlene GeeRichard Camicioli
Mar 16, 2021·Journal of Parkinson's Disease·Szu-Ju ChenChin-Hsien Lin
Jul 3, 2021·Nature Reviews. Disease Primers·Dag AarslandDaniel Weintraub
Jul 22, 2021·Scientific Reports·Min Seok BaekChul Hyoung Lyoo
Aug 4, 2021·NPJ Parkinson's Disease·Emil Ygland Rödström, Andreas Puschmann
Oct 8, 2021·Frontiers in Aging Neuroscience·Deborah L HarringtonRoland R Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Aphasia

Aphasia affects the ability to process language, including formulation and comprehension of language and speech, as well as the ability to read or write. Here is the latest research on aphasia.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.